Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Selecta Biosciences (SELB) Share Price

Press coverage about Selecta Biosciences (NASDAQ:SELB) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Selecta Biosciences earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.725846896499 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

NASDAQ:SELB traded up $0.02 during trading hours on Thursday, reaching $12.91. The company had a trading volume of 3,533 shares, compared to its average volume of 239,469. The company has a current ratio of 4.96, a quick ratio of 4.96 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $308.17 million, a price-to-earnings ratio of -4.03 and a beta of -3.67. Selecta Biosciences has a twelve month low of $7.95 and a twelve month high of $24.02.

Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Selecta Biosciences had a negative return on equity of 150.84% and a negative net margin of 31,556.04%. equities analysts predict that Selecta Biosciences will post -3.13 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on SELB shares. Canaccord Genuity reiterated a “buy” rating and set a $40.00 price objective on shares of Selecta Biosciences in a research report on Thursday, June 28th. Janney Montgomery Scott started coverage on shares of Selecta Biosciences in a report on Wednesday, June 27th. They issued a “buy” rating and a $33.00 price target for the company. Mizuho restated a “buy” rating and issued a $30.00 price target on shares of Selecta Biosciences in a report on Thursday, August 9th. BidaskClub upgraded shares of Selecta Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 9th. Finally, ValuEngine upgraded shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $28.25.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

See Also: Closed-End Mutual Funds

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply